Developer · GHRS · Ireland
GH Research PLC
GH Research is a clinical-stage pharmaceutical company developing inhaled mebufotenin (5-MeO-DMT, GH001) and related candidates for psychiatric and neurological disorders, with a lead program in treatment-resistant depression. The company is headquartered in Dublin, Ireland and listed on Nasdaq.
Pipeline (1)
- Treatment-resistant depressionPhase 2Active
- Bipolar depressionDiscontinuedDiscontinued
- Postpartum depressionPhase 2Active
Catalysts · 0 upcoming · 3 reported
Recently reported
- 2026-06-03met
Mebufotenin (inhaled 5-MeO-DMT, GH001)forPostpartum depressionFull results
Phase 2a postpartum depression results published in Journal of Clinical Psychiatry (DOI 10.4088/JCP.25m16284)
- 2025-01-10met
Mebufotenin (inhaled 5-MeO-DMT, GH001)forBipolar depressionTopline data
GH001 met primary endpoint in Phase 2a bipolar II depression POC: -16.8-point (51.9%) MADRS reduction at Day 8 (p=0.0099), 33% Day-8 remission (n=6)
- 2025-01-10met
Mebufotenin (inhaled 5-MeO-DMT, GH001)forPostpartum depressionTopline data
GH001 Phase 2a POC in postpartum depression met primary endpoint: -35.4-point MADRS reduction at Day 8 (p<0.0001), 100% remission
Recent activity
- Jun 3, 2026ReadoutMebufotenin (inhaled 5-MeO-DMT, GH001)·Postpartum depressionmetPhase 2a postpartum depression results published in Journal of Clinical Psychiatry (DOI 10.4088/JCP.25m16284)source ↗
- Jan 5, 2026Phase changeMebufotenin (inhaled 5-MeO-DMT, GH001)·Treatment-resistant depressionPhase 2FDA lifted clinical hold on GH001; global pivotal Phase 3 in TRD planned for 2026.source ↗
- Feb 3, 2025Phase changeMebufotenin (inhaled 5-MeO-DMT, GH001)·Treatment-resistant depressionPhase 2Phase 2b in TRD met primary endpoint: -15.5-point placebo-adjusted Day-8 MADRS (p<0.0001), 57.5% remission vs 0%.source ↗
- Jan 10, 2025ReadoutMebufotenin (inhaled 5-MeO-DMT, GH001)·Bipolar depressionmetGH001 met primary endpoint in Phase 2a bipolar II depression POC: -16.8-point (51.9%) MADRS reduction at Day 8 (p=0.0099), 33% Day-8 remission (n=6)source ↗
- Jan 10, 2025ReadoutMebufotenin (inhaled 5-MeO-DMT, GH001)·Postpartum depressionmetGH001 Phase 2a POC in postpartum depression met primary endpoint: -35.4-point MADRS reduction at Day 8 (p<0.0001), 100% remissionsource ↗
- Dec 5, 2024Phase changeMebufotenin (inhaled 5-MeO-DMT, GH001)·Bipolar depressionDiscontinuedGH001-BD-202 (NCT05839509) terminated after enrolling 6 of a planned larger cohort; sponsor concluded recruitment was more challenging than anticipated and that sufficient participants had completed to establish proof of concept. Bipolar II not advanced as a lead program (TRD prioritized). (Trial completion date 2024-12-05; status change reflects program closure.)source ↗
- Mar 2, 2023Phase changeMebufotenin (inhaled 5-MeO-DMT, GH001)·Postpartum depressionPhase 2Phase 2a open-label proof-of-concept trial of inhaled GH001 in postpartum depression (NCT05804708) initiated (study start date).source ↗
Competitive landscape
Other companies developing against GH Research PLC's targets or indications.
- Alto Neuroscience, Inc.2 compoundsTreatment-resistant depressionBipolar depression
- Atai Beckley N.V. (AtaiBeckley)1 compound5-HT2ATreatment-resistant depression
- Beckley Psytech Limited2 compounds5-HT2ATreatment-resistant depression
- COMPASS Pathways plc1 compound5-HT2ATreatment-resistant depression
- Intra-Cellular Therapies, Inc.2 compounds5-HT2ABipolar depression
- Reunion Neuroscience Inc.1 compound5-HT2APostpartum depression
- ACADIA Pharmaceuticals Inc.1 compound5-HT2A
- Autobahn Therapeutics, Inc.1 compoundBipolar depression
- Definium Therapeutics, Inc.1 compound5-HT2A
- Delix Therapeutics, Inc.1 compound5-HT2A
- Gilgamesh Pharmaceuticals, Inc.1 compound5-HT2A
- Helus Pharma2 compounds5-HT2A
